Dacomitinib was evaluated in a multicenter open-label phase II in 30 patients with recurrent glioblastoma (split across cohort A with EGFR gene amplification without EGFRvIII, and cohort B with both EGFR gene amplification and EGFRvIII), with the drug dosed at 45 mg daily. Here, EGFR is linked to glioblastoma.